Navigation Links
Ferring to Highlight Phase 3 Data for Cervical Ripening Candidate at Society for Maternal-Fetal Medicine Annual Meeting
Date:2/12/2013

SAN FRANCISCO, Feb. 12, 2013 /PRNewswire/ -- Ferring Pharmaceuticals will present pivotal Phase 3 efficacy and safety data from its EXPEDITE* study for its investigational controlled release misoprostol vaginal insert (MVI) at the 33rd annual meeting of the Society for Maternal-Fetal Medicine (SMFM) in San Francisco, February 11 - 16. These and other research findings formed the basis for Ferring's New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) supporting the use of the controlled release MVI as a treatment option for cervical ripening as part of the labor induction process.

Studies accepted for presentation include

  • An oral presentation on Sat., Feb. 16 (9 a.m. – 9:15 a.m. PST), titled "Efficacy and safety of misoprostol vaginal insert compared with dinoprostone vaginal insert for labor induction" (lead author: Deborah A. Wing , MD, University of California, Irvine); and
  • A poster presentation on Thurs., Feb. 14 (3:30 p.m. – 5:30 p.m. PST), titled "Comparison of misoprostol vaginal insert and dinoprostone vaginal insert: incidence of treatment-emergent adverse events" (lead author: Stacey Ehrenberg-Buchner , MD, University of Michigan Health System).

*The EXPEDITE Study: A Phase 3, double blind, randomized, multicenter study of exogenous prostaglandin comparing the efficacy and safety of the misoprostol vaginal insert (MVI) 200 mcg to the dinoprostone vaginal insert for reducing time to vaginal delivery in pregnant women at term.

For further information, contact:
Leila Boukassi
MSL New York
leila.boukassi@mslgroup.com; 646.500.7735 

About Ferring Pharmaceuticals:
Ferring Pharmaceuticals is a research-driven speciality b
'/>"/>

SOURCE Ferring Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. ESTEVE Fosters R & D by Transferring its Center for Drug Discovery to the Science Park of Barcelona (PCB)
2. Ferring Pharmaceuticals Inc. Named 10th Fastest Growing New Jersey Company
3. Ferring Pharmaceuticals Inc. Recognized for Best-in-Class Work-Life Portfolio
4. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
5. Staffing and Performance Benchmarks for Quality Function Highlight New Medical Device Study
6. Isis Reports Financial Results and Highlights for First Quarter 2012
7. Delcath Highlights First Quarter 2012 And Recent Accomplishments
8. Soligenix Reports First Quarter 2012 Financial Results and Highlights Recent Accomplishments
9. Volcano to Highlight its Leadership in Precision Guided Therapy at EuroPCR 2012
10. "Emergency Medical Services Week" Highlights Stroke Survivors and Awareness
11. PharMEDium Highlights Enhanced Labeling for ICU Services at Critical Care Expo
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... 19, 2014 Luoxis Diagnostics, Inc. ... (NYSE MKT: AMPE), today announced an upcoming ... of the American Academy of Surgical Trauma (AAST) ... Philadelphia, Pennsylvania that will ... report results from a recently completed five-year prospective ...
(Date:8/18/2014)... Japan , Aug. 19, 2014 Boston ... INTECC (Securities Code 7747, Second Section, Tokyo ... to develop a new, differentiated fractional flow reserve (FFR) ... intended to improve handling compared to existing FFR wires. ... in interventional cardiology that exceeds $250 million worldwide and ...
(Date:8/18/2014)... , Aug. 18, 2014 Reportlinker.com ... is available in its catalogue: ... http://www.reportlinker.com/p01597713/Bioseparation-Systems-for-Global-Biopharmaceutical-Markets.html ... into three types: chromatography, membranes/filters and centrifuges. ... increasing and fueling growth of the global ...
Breaking Medicine Technology:Luoxis Announces Presentation of Positive Clinical Findings from Five-Year Clinical Study of Traumatic Brain Injury and Oxidation-Reduction Potential at 2014 American Academy of Surgical Trauma Meeting 2Luoxis Announces Presentation of Positive Clinical Findings from Five-Year Clinical Study of Traumatic Brain Injury and Oxidation-Reduction Potential at 2014 American Academy of Surgical Trauma Meeting 3Boston Scientific and ASAHI INTECC Announce Joint Development and Manufacturing Programs 2Boston Scientific and ASAHI INTECC Announce Joint Development and Manufacturing Programs 3Boston Scientific and ASAHI INTECC Announce Joint Development and Manufacturing Programs 4Bioseparation Systems for Global Biopharmaceutical Markets 2Bioseparation Systems for Global Biopharmaceutical Markets 3Bioseparation Systems for Global Biopharmaceutical Markets 4Bioseparation Systems for Global Biopharmaceutical Markets 5Bioseparation Systems for Global Biopharmaceutical Markets 6Bioseparation Systems for Global Biopharmaceutical Markets 7Bioseparation Systems for Global Biopharmaceutical Markets 8Bioseparation Systems for Global Biopharmaceutical Markets 9Bioseparation Systems for Global Biopharmaceutical Markets 10Bioseparation Systems for Global Biopharmaceutical Markets 11Bioseparation Systems for Global Biopharmaceutical Markets 12
... 2011 Rigel Pharmaceuticals, Inc. (Nasdaq: ... previously announced underwritten public offering of 16,300,000 shares of ... per share to the public. The gross proceeds to ... $130,400,000, before deducting underwriting discounts and commissions, and other ...
... 26, 2011 American Scientific Resources, Inc. (OTCQB: ASFX) ... and Sanomedics International Holdings, Inc., and its affiliates, have ... United States District Court for the Southern District of ... judge, Hon. Ursula Ungaro, and the case has been ...
Cached Medicine Technology:Rigel Announces Pricing of Public Offering of Common Stock 2Rigel Announces Pricing of Public Offering of Common Stock 3American Scientific Resources, Inc. Announces Dismissal of Sanomedics International Holdings, Inc. lawsuit 2
(Date:8/20/2014)... DC (PRWEB) August 20, 2014 Hope ... Heart, Give Hope® Celebration to be hosted in Washington, ... and Navy Club. This signature event honors the courage ... families of the fallen. Proceeds from the Got Heart, ... a national nonprofit dedicated to restoring a sense of ...
(Date:8/20/2014)... Building on growing success by applying ... iii and iv pressure ulcers with extremely high ... A company spokesperson commented that these accuracy levels ... settings. The resulting capabilities can be extended to ... to help providers avoid financial losses while improving ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 Blaine ... the innovative RevitaDERM® Psoriasis Treatment to ... associated with psoriasis. This all-in-one product was created ... RevitaDERM® Psoriasis Treatment is powered by coal tar ... associated with this effective ingredient. , RevitaDERM® ...
(Date:8/20/2014)... 2014 AttorneyOne.com, a recognized authority on law, ... the FDA on Sodium Chloride IV . , ... of Sodium Chloride IV 0.9%, USP 1000 mL, by Baxter ... of particulate matter. Sodium Chloride Injection, USP is used as ... solution in hemodialysis procedures. , The reason for ...
(Date:8/20/2014)... NY (PRWEB) August 20, 2014 At this ... of Africa. To help eliminate the root cause of the ... recently teamed up with the nonprofit organization Books For Africa ... Africans: How Every African Can Live the Life of Their ... , This book equips Africans with the tools they need ...
Breaking Medicine News(10 mins):Health News:Hope For The Warriors Announces Got Heart, Give Hope Celebration in Washington, DC 2Health News:Jvion Achieves Benchmark Accuracy in Pressure Ulcer Prediction 2Health News:RevitaDERM® Psoriasis Treatment Now Available At Over 7,600 CVS/pharmacies 2Health News:Sodium Chloride IV 0.9% by Baxter Recalled: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Ebola, Poverty, and a Partnership for Africa—How Everyone Can Help 2Health News:Ebola, Poverty, and a Partnership for Africa—How Everyone Can Help 3
... broader, patient-centered treatment choices to those ... dealing with substance use disorders, WASHINGTON, ... awarded a $7 million contract to provide technical,assistance to the ... Mental Health Services Administration (SAMHSA) within,the U.S. Department of Health ...
... Serious subject for the funnies becomes basis for Lisa,s Legacy ... in a comic strip,Funky Winkerbean creator Tom Batiuk has depicted ... of breast cancer. Lisa Moore, a major,character who is battling ... Oct. 4, 2007, leaving behind her husband, Les, and their,five-year-old ...
... 2, 2007 Phylonix Pharmaceuticals, Inc. today announced that it ... Grant (SBIR) from the National Eye Institute of the National ... for drug screening. The grant for New Models for ... of three years., The eye is a highly conserved organ ...
... Paramed Systems announced today,the release of their Mobility Offers ... fire, emergency medical, and,rehabilitating patients safely and easily both ... a button. Paramed developed the dual-track MOV in ... capable of safe stairway ascents and,descents. The MOV has ...
... a Full-featured Solution for Home ... DALLAS, Oct. 2 Today, Dynamic Energy Systems, Inc.,(DES) ... on- demand, on-line software solution. The online version,provides access ... so excited to offer our customers a choice when ...
... the Modernization, of its Health Information System Based on BEA ... ... (Assistance Publique - Hopitaux de Marseille) has chosen BEA ... Integration offers an interoperability platform upon which AP-HM has built ...
Cached Medicine News:Health News:Altarum Wins $7 Million Contract to Provide Technical Assistance to the Access to Recovery Program 2Health News:University Hospitals Ireland Cancer Center and Funky Winkerbean Cartoonist Tom Batiuk Establish Lisa's Legacy Fund for Cancer Research and Education 2Health News:University Hospitals Ireland Cancer Center and Funky Winkerbean Cartoonist Tom Batiuk Establish Lisa's Legacy Fund for Cancer Research and Education 3Health News:University Hospitals Ireland Cancer Center and Funky Winkerbean Cartoonist Tom Batiuk Establish Lisa's Legacy Fund for Cancer Research and Education 4Health News:NIH awards Phylonix phase II SBIR to develop zebrafish models for eye diseases 2Health News:AP-HM Places Patients at the Core of its Service-Oriented Architecture with BEA Systems 2Health News:AP-HM Places Patients at the Core of its Service-Oriented Architecture with BEA Systems 3Health News:AP-HM Places Patients at the Core of its Service-Oriented Architecture with BEA Systems 4Health News:AP-HM Places Patients at the Core of its Service-Oriented Architecture with BEA Systems 5
Femoral selective diagnostic catheter.The material used is polyurethane (DUCOR). All selective shapes have thrulumen design. Guidewire campatibility is 0.038". Packaging 5/Box....
Jography angiographic catheter has a new material combination, a patented angled weld, a flat wire braid design with a XXL lumen. It also has an atraumatic soft tip....
Femoral selective diagnostic catheter. The material used is nylon (VESTANTM). All selective shapes have thrulumen design. Guidewire campatibility is 0.038". Packaging 5/Box....
... of cardiology catheters. Available in both Softouch ... with excellent torque, new wire-braid technology for ... large inner lumens for excellent flow rates. ... French sizes with pressure ratings up to ...
Medicine Products: